Drug Trial Radar · NCT01114737
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients
Last checked: Nov 20, 2026Latest source record: Feb 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
206
Actual
Start
Aug 2010
Primary completion
Mar 2013
Study completion Mar 2013
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- May 3, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 8 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This double-blind, placebo-controlled, randomized study is designed to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with PKU.
Conditions
- Phenylketonuria
Interventions
Sapropterin dihydrochlorideDrug
A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).
PlaceboDrug
Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Attention-Deficit Hyperactivity Disorder Rating Scale-IV (ADHD-RS) / Adult ADHD Self-Report Scale (ASRS) Total Score From Baseline to Week 13Time frame: Baseline to Week 13
- Number of Participants With a Score of 1 or 2 in Global Function Evaluation (CGI-I) From Baseline to Week 13.Time frame: 13 weeks
Locations
36 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
La Jolla, California
Site not named
Los Angeles, California
Site not named
Palo Alto, California
Site not named
San Francisco, California
Site not named
Aurora, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Gainesville, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Chicago, Illinois
Site not named
Indianapolis, Indiana
Site not named
Boston, Massachusetts
Site not named
Minneapolis, Minnesota
Site not named
Albany, New York
Site not named
Buffalo, New York
Site not named
Rochester, New York
Site not named
Chapel Hill, North Carolina
Site not named
Cleveland, Ohio
Site not named
Portland, Oregon
Site not named
Hershey, Pennsylvania
Site not named
Philadelphia, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Nashville, Tennessee
Site not named
Dallas, Texas
Site not named
Madison, Wisconsin
Site not named
Milwaukee, Wisconsin
Site not named
Calgary, Alberta, Canada
Site not named
Edmonton, Alberta, Canada
Site not named
Vancouver, British Columbia, Canada
Site not named
Winnipeg, Manitoba, Canada
Site not named
Halifax, Nova Scotia, Canada
Site not named
Hamilton, Ontario, Canada
Site not named
Kingston, Ontario, Canada
Site not named
London, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.